Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 432980

MFC Co., Ltd.

Official website

MFC produces 37 MFDS-registered APIs along with key starting materials like TBFA and TPPBr for statin-class drugs.

As of 2026-10-08, MFC Co., Ltd. has 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2008, MFC listed on KOSDAQ in 2024 as an API and key material company. It has registered a total of 37 APIs with Korea's MFDS, meeting KP, USP, EP, and JP pharmacopoeia standards, producing and selling the hypertension/hyperlipidemia drugs Pitavastatin and Rosuvastatin, the chronic bronchitis drug Erdostein, the antiplatelet agent Sarpogrelate, and musculoskeletal drugs Afloqualone, Pelubiprofen, and Camostat. It also handles key materials such as TBFA, a common key starting material (KSM) for statin-class drugs, TPPBr (KSM for Pitavastatin), MRV-1 (a key pharmaceutical intermediate for Rosuvastatin), and PPCA (KSM for the DPP-4 inhibitor diabetes drug Anagliptin), and develops improved new drug materials such as MFC-TM001, MFC-RM001, MFC-GM001, and MFC-EM002 through crystal-form modification.

Products & technology

  • TBFACommon key starting material for statin-class drugs
  • TPPBrKey starting material for Pitavastatin
  • MRV-1Key pharmaceutical intermediate for Rosuvastatin
  • Pitavastatin API
  • Rosuvastatin Strontium API
  • RSVT-3T
  • Sulglycotide API
  • Trimebutine API
  • Afloqualone API
  • Pelubiprofen API
  • Camostat API
  • PPCA/AN1Key starting material for Anagliptin (endocrine disease)
  • s-Pantoprazole API
  • Erdostein APIChronic bronchitis treatment
  • Sarpogrelate APIAntiplatelet agent
  • Donepezil HCI API
  • Donepezil Base API
  • s-Amlodipine Besylate APIHypertension treatment
  • Fimasartan API (MFC-FG001)
  • Azilsartan API
  • Edoxaban APIAnticoagulant

R&D and key agreements

Source: DART corporate disclosure

MFC-TM001 · 소화계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development

MFC-IM001 · 소화계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development

MFC-RM001 · 순환계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development

MFC-GM001 · 당뇨병 치료제 · 개량신약원료 개발 · Salt or crystal-form modification development

MFC-EM002 · 항응고제 · 개량신약원료 개발 · Salt or crystal-form modification development

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 48 more patents

AI reads

MAA server logs · IP-verified
13
Times AI engines pulled MFC Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

11
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

0
live 0
Last 7 days
8
live 2
Last 30 days
13
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot5
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Sep 29, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for MFC Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition